These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8577151)

  • 1. [Prophylactic and sensitizing effects of biologically active substances in animal modeling of vestibular disorders].
    Shashkov VS; Drozd IuV; Puko VM
    Kosm Biol Aviakosm Med; 1991; 25(5):61-3. PubMed ID: 8577151
    [No Abstract]   [Full Text] [Related]  

  • 2. New pharmacologic approaches to spinal cord injury: opiate antagonists and thyrotropin-releasing hormone.
    Faden AI
    Cent Nerv Syst Trauma; 1985; 2(1):5-8. PubMed ID: 3004747
    [No Abstract]   [Full Text] [Related]  

  • 3. Preparation of ion-activated in situ gel systems of scopolamine hydrobromide and evaluation of its antimotion sickness efficacy.
    Cao SL; Zhang QZ; Jiang XG
    Acta Pharmacol Sin; 2007 Apr; 28(4):584-90. PubMed ID: 17376300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison between two anti-motion sickness drugs].
    Wang J; Qian JK; Wang BZ; Gao JY; Shi HZ
    Space Med Med Eng (Beijing); 1999 Apr; 12(2):138-40. PubMed ID: 12430546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Investigation of the anti-motion sickness effect of 3-hydroxypyridine derivatives].
    Iasnetsov VV; Pravdivtsev VA; Shashkov AV; Smirnov LD; Iasnetsov VV; Kozlov SB; Ivanov IuV
    Aviakosm Ekolog Med; 2005; 39(4):45-50. PubMed ID: 16353627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Transdermally applied scopolamine for continuous prevention of motion sickness. Revival of a 150-year-old method].
    Becker G
    Schweiz Rundsch Med Prax; 1985 Mar; 74(11):271-6. PubMed ID: 3887535
    [No Abstract]   [Full Text] [Related]  

  • 7. Antimotion sickness and antiemetic drugs.
    Wood CD
    Drugs; 1979 Jun; 17(6):471-9. PubMed ID: 467277
    [No Abstract]   [Full Text] [Related]  

  • 8. [Model of motion sickness in white mice experiments].
    Zhabko EP; Lukomskaia NIa
    Aviakosm Ekolog Med; 1997; 31(6):66-8. PubMed ID: 9483286
    [No Abstract]   [Full Text] [Related]  

  • 9. [Neurochemical mechanisms of the development of motion sickness].
    Iasnetsov VV; Shashkov VS
    Vestn Ross Akad Med Nauk; 1992; (7):16-21. PubMed ID: 1281702
    [No Abstract]   [Full Text] [Related]  

  • 10. Control of simulator sickness in an AH-64 aviator.
    Crowley JS
    Aviat Space Environ Med; 1990 Jun; 61(6):584-5. PubMed ID: 2369402
    [No Abstract]   [Full Text] [Related]  

  • 11. [Comparative in-flight study of a scopolamine-containing membrane plaster versus dimenhydrinate under defined acceleration conditions].
    Offenloch K; Zahner G; Dietlein G; Franz I
    Arzneimittelforschung; 1986 Sep; 36(9):1401-6. PubMed ID: 3539128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Central effects of a selective delta-opioid receptor antagonist, ICI 174864.
    Herman ZS; Stańda J; Janas P; Gołba K
    Pol J Pharmacol Pharm; 1986; 38(5-6):455-60. PubMed ID: 3575165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of anti-motion sickness drugs on motion sickness in rats.
    Morita M; Takeda N; Kubo T; Yamatodani A; Wada H; Matsunaga T
    ORL J Otorhinolaryngol Relat Spec; 1988; 50(5):330-3. PubMed ID: 3186231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of naloxone on motion sickness in cats alone and with broad spectrum antiemetics.
    Lucot JB
    Auton Neurosci; 2017 Jan; 202():97-101. PubMed ID: 27615675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic control of vomiting.
    Davis LE
    J Am Vet Med Assoc; 1980 Feb; 176(3):241-2. PubMed ID: 7364635
    [No Abstract]   [Full Text] [Related]  

  • 16. [Vestibulo-protective properties of regulatory peptides].
    Drozd IuV; Iasnetsov VV; Shashkov VS
    Biull Eksp Biol Med; 1988 Jul; 106(7):50-2. PubMed ID: 2456793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A rotational syndrome induced by administration of the delta sleep-inducing peptide into the reticular portion of the rat substantia nigra].
    Shandra AA; Godlevskiĭ LS; Vast'ianov RS; Zaporozhchenko MB; Ibragim M; Brusentsov AI; Oleĭnik AA
    Fiziol Zh Im I M Sechenova; 1996; 82(10-11):69-72. PubMed ID: 9162398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychophysiological aspects of motion sickness.
    Murray JB
    Percept Mot Skills; 1997 Dec; 85(3 Pt 2):1163-7. PubMed ID: 9450266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled-release transdermal drug delivery.
    Kelly HW
    Cutis; 1985 Mar; 35(3):204, 207. PubMed ID: 3920010
    [No Abstract]   [Full Text] [Related]  

  • 20. Hyperalgesia produced by intrathecal opioid antagonists depends on receptor selectivity and noxious stimulus.
    Pilcher CW; Browne JL
    NIDA Res Monogr; 1986; 75():469-72. PubMed ID: 2828994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.